title: A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia.
authors.affiliation: Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK.
authors.forename: M W
authors.initials: MW
authors.lastname: Drummond
authors.affiliation: Department of Hematology, East Kent Hospitals, Canterbury, UK.
authors.forename: C
authors.initials: C
authors.lastname: Pocock
authors.affiliation: Leeds Institute for Cancer Studies and Pathology, University of Leeds, Leeds, UK.
authors.forename: M
authors.initials: M
authors.lastname: Boissinot
authors.affiliation: Worcestershire Acute Hospitals NHS Trust and University of Birmingham, Birmingham, UK.
authors.forename: J
authors.initials: J
authors.lastname: Mills
authors.affiliation: Clinical Trials Research Unit, University of Leeds, Leeds, UK.
authors.forename: J
authors.initials: J
authors.lastname: Brown
authors.affiliation: Institute of Biomedical Research, University of Birmingham, Birmingham, UK.
authors.forename: P
authors.initials: P
authors.lastname: Cauchy
authors.affiliation: Faculty of Medicine, University of Southampton, Southampton, UK.
authors.forename: N C P
authors.initials: NC
authors.lastname: Cross
authors.affiliation: Clinical Trials Research Unit, University of Leeds, Leeds, UK.
authors.forename: S
authors.initials: S
authors.lastname: Hartley
authors.affiliation: Department of Hematology, University Hospital of Wales, Cardiff, UK.
authors.forename: J
authors.initials: J
authors.lastname: Kell
authors.affiliation: Clinical Trials Research Unit, University of Leeds, Leeds, UK.
authors.forename: A
authors.initials: A
authors.lastname: Szubert
authors.affiliation: Institute of Biomedical Research, University of Birmingham, Birmingham, UK.
authors.forename: P N
authors.initials: PN
authors.lastname: Cockerill
authors.affiliation: Department of Hematology, St James's Institute of Oncology, Leeds, UK.
authors.forename: D T
authors.initials: DT
authors.lastname: Bowen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine